ReviewDrug design, development and therapy2026
Tubulin Post-Translational Modifications in Cardiovascular Diseases: Emerging Mechanisms and Therapeutic Modulation by Traditional Chinese Medicine.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) severely threaten human health, and microtubule dysfunction is one of the major contributing factors. Tubulin post-translational modifications (PTMs), such as detyrosination, acetylation, and polyglutamylation, regulate microtubule homeostasis, among which the upregulation of detyrosination is a key feature of cardiovascular diseases. Traditional Chinese Medicine (TCM) can alleviate cardiac pathologies by targeting these modifications. This review discusses the driving mechanisms of PTMs in relation to the pathological changes that occur in CVDs and summarizes the therapeutic effects of traditional Chinese Medicine targeting these modifications that have been identified in recent years. By systematically searching databases such as PubMed, it was found that PTMs primarily control the stability and contractility of the microtubule cytoskeleton in cardiomyocytes. Their dysregulation promotes the progression of diseases such as myocardial infarction (MI), atherosclerosis (AS), arrhythmias, and cardiac hypertrophy by disrupting key processes including mitochondrial energy metabolism, inflammasome activation, calcium homeostasis, and oxidative stress (OS). Certain active compounds found in TCM, such as curdione, evodiamine, and tanshinone IIA (Tan-IIA), can modulate PTMs through the synergistic regulation of multiple pathways. This review provides a theoretical basis for establishing TCM-based therapeutic strategies for CVDs that target PTMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.